focus -WSS

focus

author：leisure time 2025-08-30 19:12:39 - browse：866

Fran van Delft for Galapagos

Seeking to differentiate itself from other makers of CAR-T cancer therapies, Galapagos NV on Wednesday announced it had struck a deal with Blood Centers of America to open up dozens of manufacturing sites for its cell-based medicines around the U.S.

Galapagos said it will rely on the partnership, the financial terms of which were not disclosed, as it moves its CAR-Ts for different cancers into pivotal studies and could also help launch those medicines should they win approval. The Belgian company framed the collaboration as one that could help overcome the limitations that have held back access to existing CAR-T therapies from other companies.

CAR-Ts have proven to be potent treatments for certain cancers, but they are complicated medicines to make. Immune cells have to be removed from a patient, shipped to specialty sites, where they’re engineered with cancer-killing abilities, and then returned to the hospital for infusion back into patients. The process, which can take weeks if not months, has put a crunch on the number of patients companies and hospitals are able to treat.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： Gritstone Bio's cancer vaccine test, and more on Novartis' deal

WSS

UHS says company favors patients whose insurance pays more

Surgery pushed Ben Carson to fame

A new crop of companies is reshaping the health data economy

Truvian presents data for its desktop blood

Readout LOUD: Venture capital, Gilead, and more M&A

The haunting brain science of long Covid

hotspot

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

entertainment

23andMe had bad news about my health. I wish a person had delivered it

340B reform proposal comes out of Senate working group

Tori Bowie and the unacceptable rates of Black maternal death

Updated Covid vaccine has 54% effectiveness, new study suggests

Psychedelics group wrestles with new pharma identity

A new crop of companies is reshaping the health data economy

Dobbs anniversary: the lost opportunity of abortion as health care

Unique patient identifier: Experts argue the benefits, pitfalls

Alkermes shareholders re

AI gets buy

leisure time

Senate panel puts off hardest PBM reforms for another day

Johnson & Johnson sued for allegedly overpaying for workers' drugs

Rise in cancer among younger people worries and puzzles doctors

Texas Medical Board asked to define abortion emergency exception

Truvian presents data for its desktop blood

Device maker Teleflex to acquire urology company for $600M

explore

hotspot

hotspot

focus